The US Food and Drug Administration (FDA) todayapprovedthe combination ofnivolumab(Opdivo, Bristol-Myers Squibb) plusipilimumab(Yervoy, Bristol-Myers Squibb) as first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) whose tumors express PD-L1 (≥ 1%). Use is limited...
to use certain anti-cancer agents.Drugs such as tyrosine kinase inhibitors,anaplastic lymphoma kinase inhibitors,and monoclonal antibodies possess limited utility because they target specific oncogenic mutations,but other drugs that target mechanisms universal to all cancers do not.In this review,we ...
With the introduction of personalized medicine, physicians are increasingly aware of when, how, and in whom, to use certain anti-cancer agents. Drugs such as tyrosine kinase inhibitors, anaplastic lymphoma kinase inhibitors, and monoclonal antibodies possess limited utility because they target specific ...
Neoadjuvant immune checkpoint inhibitor (ICI) treatment + chemotherapy has been used for locally advanced non-small cell lung cancer (NSCLC); however, evid... Y Yang,Z Liu - 《Oncology Letters》 被引量: 0发表: 2023年 Optimizing the combination of chemotherapeutic drugs along with radiotherapy fo...
chemotherapyforstageIIIunresectablenon-smallcelllung cancer BeiLu•LixinSun•XiYan•ZhenzhongAi• JinzhiXu Received:7November2014/Accepted:9November2014/Publishedonline:28November2014 Science+BusinessMediaNewYork2014 Theaimofthestudywastoevaluatetheeffi-observed.ElevenstageIIIApatientsunderwentsurgery,for ...
FDA approves osimertinib with chemotherapy with chemotherapy for EGFR-mutated non-small cell lung cancer. FDA. February 16, 2024. Accessed February 16, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-chemotherapy-egfr-mutated-non-small-cell-lung-cancer Ta...
FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer. News release. FDA. March 4, 2022. Accessed June 29, 2023.https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-nivolumab-and-platinum-doublet-chemotherapy...
5 It has proven efficacy against multiple cancers, including breast, ovarian, prostate and NSCLC and small cell lung cancer.6 Taxanes such as PTX and docetaxel are highly effective for the treatment of cancer and several other diseases. These drugs target the microtubule cytoskeleton that is ...
A. Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts, said in a news release. "ALK now becomes the second abnormal gene that we are able to successfully target in lung cancer with drugs other than chemotherapy....
Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383(9928):1561-1571. doi:10.1016/S0140-6736(13)62159-5 PubMedGoogle ScholarCrossref 16. McGuinness LA, Higgins JPT. Risk-of-bias ...